Thymus and Mediastinal Node Involvement in Childhood Langerhans Cell Histiocytosis: Long-Term Follow-Up From the French National Cohort

Stephane Ducassou, MD,1,2* Fanny Seyrig, MD,3 Caroline Thomas, MD,3 Anne Lambilliotte, MD,4 Perrine Marec-Berard, MD,5 Claire Berger, MD,6 Genevieve Plat, MD,7 Laurence Brugiere, MD,8 Marie Ouache, MD,9 Mohamed Barkaoui, MSc,10 Corinne Armari-Alla, MD,11 Patrick Lutz, MD, PhD,1 Guy Leverger, MD,10 Xavier Rialland, MD,12 Ludovic Mansuy, MD,13 Helene Pacquement, MD,14 Eric Jeziorski, MD, PhD,15 Virginie Gandemer, MD, PhD,16 François Chalard, MD,17 Jean François Chatel, MD, PhD,18 Abdellatif Tazi, MD, PhD,19 Jean François Emile, MD, PhD,20 Jean Donadieu, MD, PhD,10 and the Investigators of the French LCH Study Group

Background. Mediastinal involvement (MI) in Langerhans cell histiocytosis (LCH) has been rarely reported. Here, we describe the clinical, radiological, and biological presentation, and the outcome of childhood LCH with MI. Method. From the French LCH register, which includes 1,423 patients aged less than 18 years, we retrieved the medical charts of patients with mediastinal enlargement detected on chest X-rays. Results. Thirty-seven patients were reviewed, including 18 males; median age of diagnosis was 0.7 years, and median follow-up time was 6.2 years. The prevalence of MI varied with the age at diagnosis, ranging from 7% below 1 year old to less than 1% at >5 years. Thirteen cases (35%) were diagnosed because of MI-related symptoms, including respiratory distress (N = 4), superior venous cava syndrome (N = 2), and/or cough and polyneuropathy (N = 10). CT scans performed in 32 cases at diagnosis showed tracheal compression (N = 5), cava thrombosis (N = 2), and/or calcification (N = 16). All patients presented multi-system disease at LCH diagnosis, and 35/37 were initially treated with vinblastine and corticosteroids. Death occurred in five cases, due to MI (N = 1) or hematological refractory involvement (N = 4). The overall 5-year survival was 87.1%, and immunodeficiency was not detected as a sequel. Conclusions. MI in LCH mainly occurs in young children, and diagnosis was based on CT showing thymus enlargement and calcifications. Pediatr Blood Cancer 2013;60:1759–1765.

INTRODUCTION

Langerhans cell histiocytosis (LCH) is a disease characterized by accumulation of Langerhans cells in various tissues or organs; about half of cases involve mutation of the B-ráf oncogene [1]. LCH clinical presentation and outcome are heterogeneous, ranging from an isolated spontaneously remitting lesion to a multi-system disease including sometimes life-threatening organ dysfunction [2]. Rarely, thymus and mediastinal lymph node involvement is observed; an exhaustive literature search covering 50 years identified no more than 50 cases reported to date (Table I). In the present study, we use a clinical national registry that was established in 1993 to systematically review all patients with LCH who presented thymic or mediastinal involvement (MI). Using this information, we describe the natural history of this rare involvement in LCH.

METHODS

Patients

LCH diagnosis was based on the Histiocyte Society criteria [3], including morphologic features of histiocytic granuloma and additional criteria, such as CD1a expression. The French Langerhans’ Cell Histiocytosis Study Group database was initially created for a retrospective study of LCH from 1983 to 1993 [2]; since then, enrollment has been prospective. From April 1996 to November 2001, eligible patients have been included in Histiocyte Society clinical trials (the LCH II and LCH III studies). Since 2008, this collection of data has been recognized as a national register by the French health authorities and has been verified against multiple separate sources [4]. The database has been allowed by the French authorities for health data collection (Comité Consultatif pour le Traitement de l’Information en Matière de Recherche pour la Santé [CCTIRS]) and Commission Nationale Informatique et Liberté (CNIL). DOI 10.1002/pbc.24603

© 2013 Wiley Periodicals, Inc.
Published online 29 June 2013 in Wiley Online Library (wileyonlinelibrary.com).
| Publication year | No. of cases | Age (years) | Clinical symptoms | Follow-up/outcome |
|------------------|--------------|-------------|-------------------|--------------------|
| **Pediatric cases of Langerhans cell histiocytosis with thymic involvement** | | | | |
| 1963 [5] | 1 | 12 | Arthralgia, headache, anorexia | 2 years/alive |
| 1982 [6] | 1 | 1.25 | Cough/weakness/anorexia | 6 months/alive |
| 1985 [7] | 4 | 5, 8, 5, and 0.2 | No symptoms (2)/low back pain (1)/respiratory distress (1) | 4.4 years/alive |
| 1986 [8] | 1 | 0.66 | No respiratory symptoms | Alive after one relapse |
| 1985 [9] | 1 | 1.5 | No respiratory symptoms, soft swelling of the forehead, lung X-rays abnormal | MD |
| 1987 [10] | 4 | 2, 1, 3, and 1.3 | Shortness of breath (2)/no respiratory signs (2) | 3.5, 4, or 20 years/alive |
| 1987 [11] | 2 | 0.3 | Lymph node enlargement, slight dyspnea and perioral subcyanosis (1)/polypnea, subcyanosis, and hepatosplenomegaly | 2 years and 3 months/alive |
| 1987 [12] | 1 | 0.4 | Jaundice, MOF, thymic involvement | 11 months/dead |
| 1991 [13] | 2 | 0.4 | Tachypnea (1) or general signs (1) | 5 years/alive |
| 1993 [14] | 1 | 1.5 | Superior vena cava syndrome | 1 years/alive |
| 1993 [15] | 1 | 0.05 | Respiratory distress | No relapse |
| 1997 [16] | 1 | 0.6 | Pulmonary symptoms, skin, liver, lymph nodes | 10 years/alive |
| 1999 [17] | 4 | 0.7 | MD | Alive |
| 1999 [18] | 5 | 1.9 (median value) | MD | Alive |
| 1999 [19] | 1 | 2 | No respiratory symptoms/abdominal pain | MD |
| 2000 [20] | 1 | 1.6 | 6 months of progressive dyspnea | MD |
| 2002 [21] | 1 | 0.3 | Feeding difficulties, poor weight gain, SS | 3 years/alive |
| 2006 [22] | 3 | 0.8 | MS disease | 6 months/dead, 2 years/dead, 8 years/alive |
| 2007 [23] | 1 | MD | MD | MD |
| 2008 [24] | 1 | 1.5 | Breathing difficulty, fever | MD |
| 2008 [25] | 2 | 0.4 (for the two patients) | MD | MD |
| 2008 [26] | 1 | 12 | Dyspnea, chest pain, weight loss, MS histiocytosis | 1 years/alive with residual mass |
| 2009 [27] | 1 | 0.2 | Fever, cough, swelling in left supraclavicular area | 2 years/alive |
| 2009 [28] | 1 | 0.8 | SUDI, MS histiocytosis | Dead |
| 2010 [29] | 1 | 0.25 | Respiratory distress | MD |
| **Thymic involvement discovered on incidental thymectomy or post-mortem without any clinical or radiological signs** | | | | |
| 2003 [30] | 1 | 0.9 | Incidental thymectomy | 19 months after surgery/alive |
| 1986 [31] | 1 | 36 | Myasthenia gravis, few LCH cluster on thymectomy | MD |
| 1997 [32] | 1 | 30 | Myasthenia gravis, few LCH cluster on thymectomy | MD |
| 1989 [33] | 1 | 21 | Myasthenia gravis | Alive |
| 2003 [34] | 1 | 49 | 3 years after a soft tissue sarcoma: sub-sternal chest pain, leading to the discover of an anterior mediastinal mass | Alive |
| **Adult cases of Langerhans cell histiocytosis with thymic involvement** | | | | |
| 2000 [35] | 1 | 58 | Acute severe right-sided chest pain | Died 2 weeks after surgery |
| 2008 [36] | 1 | 43 | MD | Alive |

MD, missing data; MS, multi-system; SUDI, sudden infant death.
and patients or parents had to provide informed consent to be included in the registry. Data monitoring was performed by a clinical research associate who visited each center and reviewed medical and radiological charts. All patients with mediastinal node and/or thymus involvement were screened by chest X-rays, and thoracic computed tomography (CT) was performed in 32 cases. Following standard radiological practice, MI was diagnosed based on mediastinal area enlargement on chest X-rays [37]. Since anatomical thymus and mediastinal nodes enlargement may be associated and difficult to differentiate, we reported them together. When available, CT scans provided further information about mediastinal node size and aspects of the thymus, including thymic shape (nodular or lobulated), intrathymic calcifications, and cavitations. For the present study, we systematically reviewed the medical charts, and the radiological and pathological reports. Disease activity scores were based on a previous publication [38].

Statistical Methods

Stata® version 10 software was used for all statistical analyses. Median values and lower and upper interquartile values depict the distribution of quantitative variables. To calculate the reactivation rate, we considered the period from the MI to the onset of any new involvement or to the last visit if no additional involvement occurred. The Kaplan–Meier method was used to estimate survival. The cut-off date for this analysis was September 30, 2012.

RESULTS

Demography and Clinical Presentation

Of 1,423 patients enrolled in the French LCH register, 37 (2.6%) were diagnosed as having mediastinal enlargement on chest X-rays and were eligible for this study. Table II presents the demographics, organ involvement, and immunological features of these patients. They included 18 males (48%), and the median age at diagnosis of LCH was 0.7 years (IQR, 0.5–1.7 years). In four cases, the diagnosis of MI was made after the age of 10 years old. The median follow-up was 6.2 years (IQR, 1.5–11.7 years).

A majority of patients were diagnosed during their first year of life (22/37), with five patients diagnosed during their first 3 months of life. The proportion of cases with MI decreased with age, ranging from 7% in the first year of life, 4% in the second, 2% in the third, to less than 1% at >5 years. At the time of MI diagnosis, all patients had multi-system LCH, with 26 (70%) having at least one risk organ involved (liver/spleen or hematological dysfunction); lung involvement was excluded from the definition of risk organ.

MI was found at the first occurrence of the disease in 34 cases, and at the onset of reactivation in 3. The initial symptoms leading to LCH diagnosis were related to MI in 13 cases (35%); in the other cases, MI was discovered in the work-up of previously diagnosed LCH. The other initial sites of the disease were skin (28 cases, 75%), bone (21 cases, 56%), lung (15 cases, 40%), hematopoietic system (17 cases, 46%), and liver (16 cases, 43%). The disease scores ranged from 2 to 16 (median score, 5), with only 11 patients categorized as high risk (score >6) and a majority of patients (N = 24) being of intermediate risk (score of 3–6). Twenty-three patients had general symptoms, that is, fever more than 38.5˚C and asthenia with Karnofsky indice minor than 80%. Clinical symptoms preceding the observation of MI varied: 10 had only a cough, 4 had respiratory distress, 2 had superior vein cava syndrome, and 1 had tachypnoea without distress. Among the 15 patients with respiratory symptoms, 5 had lung involvement, which may have been partly responsible for these symptoms.

| Characteristic | At LCH thymus diagnostic, N (%) | Maximal extent of the disease, N (%) |
|---------------|--------------------------------|-----------------------------------|
| Age (years), median [IQR] | 0.7 [0.6–1.7] | 6.2 years [1.5–11.7] |
| Follow-up, median [IQR] in years | 19/18 | |
| Sex (female/male) | | |
| Disease activity score | | |
| 0–2 | 2 (5.4) | |
| 3–6 | 24 (65) | |
| >6 | 11 (30) | |
| Orgin involvement | | |
| Risk organ | | |
| Hematopoietic system | 17 (46) | 18 (48) |
| Liver | 16 (43) | 17 (46) |
| Spleen | 10 (27) | 12 (33) |
| No risk organ | | |
| Lung | 15 (40) | 18 (48) |
| Bone | 21 (56) | 24 (64) |
| General symptoms (fever/loss of weight or failure to thrive) | 23 (64) | 24 (65) |
| Hypophysis | 3 (8) | 10 (27) |
| ENT including external auditory tract and temporal bone | 13 (35) | 18 (43) |
| Central nervous system | 1 (2.7) | 4 (10) |
| Immunological disorder (% among informative patients) | | |
| Lymphopenia | 6 (19) | |
| Lymphopenia CD8⁺ | 5 (16) | |
| Hypogammaglobulinemia (<3 SD according to age) | 3 (9.7) | |
| No abnormality | 17 (54) | |
| No data | 6 | |

Pediatr Blood Cancer DOI 10.1002/pbc
At diagnosis, six patients had lymphopenia with deficiency of CD4 and CD8 T lymphocytes, which was profound in two cases among the 14 patients assessable for these criteria. Figure 1 depicts the lymphocyte status of patient UPN 1506627, both at diagnosis and during therapy; this patient’s iconography is reported in Figure 2A,B. One child had hypogammaglobulinemia. In the other patients, the immunological control was normal or not checked.

Radiological Presentation

All patients had chest X-rays at diagnosis, and 32 also had thoracic CT performed. Tomography emission positron computed tomography (PET-CT) was performed in two cases. Table III presents an overview of the CT features at diagnosis. Although the anatomic delimitation was quite difficult, it was found that 14 patients had only thymic involvement, 10 had only mediastinal lymph node involvement, and 13 had combined (thymus and lymph node) involvement. Sixteen patients presented punctuate calcifications in the thymus, which were visible on CT (Fig. 2F,G, arrowheads) but not on chest radiography. Other signs included a heterogeneous thymus in 18 patients, two of which also exhibited cysts (Fig. 2H, white arrows) besides the calcifications (Fig. 2G, arrowheads). Twelve patients had a nodular thymus with contour modifications, referred to as a polycyclic thymus. Tracheal compression was reported in five patients, tracheal deviation in five, cava vein thrombosis in two (two cases of sternum and two of vertebral erosion), and pericardic effusion in three cases. Abnormalities of the parenchymal lung (cyst or nodules) were found in six patients simultaneously with MI. MI may be analyzed as an involvement of the thymus, the mediastinal nodes or both. Such differences may be difficult to analyze on CT scan. However, if we considered our observation, patients with mediastinal nodes only were older (1.8 years) than patients with thymus only (0.8 years) and patients with thymus and nodes (1 year; \( P = 0.015 \)) while anatomic extension of the disease was about the same between the three subgroups, except the group of patients with thymus involvement which exhibited less bone involvement (41%) compared to the two other groups (80%).

Pathological Findings

LCH was histologically confirmed in all patients by demonstrating CD1a-positive cells in biopsies from bone, skin, and lymph nodes. Thymic involvement was also histologically confirmed in four patients, and mediastinal lymph nodes were biopsied in one patient. The pathological cells exhibited an eosinophilic appearance of the cytoplasm and few mitotic figures. Immunohistochemical analysis revealed strong positivity of these cells for CD1a and S-100 protein. BRAF p.V600E mutations were only studied in two patients, and were detected in both cases, including the tumor DNA obtained from one thymic sample.

Characteristics of Patients With Mediastinal Involvement Compared With the Overall Patient Sample

Some demographic features and organ involvements differed between the 37 patients with MI and the 1,386 patients without MI in the registry. Median age at diagnosis was 0.75 years in the MI group versus 3.2 years in the non-MI group (\( P < 0.001 \)). Gender did not differ between the groups. At the maximal extent of the disease, significant differences (with \( P < 0.001 \) or below) were observed between the MI group versus the non-MI group with regards to the prevalence of the organ involvement, with less bone involvement (65% vs. 82%), and more involvement of skin (78% vs. 33%), lung (49% vs. 9%), hematopoetic dysfunction (49% vs. 9%), liver (46% vs. 9.5%), and spleen (32% vs. 8%). Central nervous system and pituitary involvement did not statistically differ between the two groups. The natural history of these patients was marked by a higher rate of reactivation (48% vs. 33%; \( P = 0.01 \)) and a higher mortality rate (16% vs. 4%; \( P = 0.01 \)) compare to non-MI group.
Therapy and Outcome

Of the 34 patients with MI present at the initial LCH diagnosis, 32 were treated with corticosteroids (prednisone) at a dose of 40 mg/m²/day and vinblastine (6 mg/m²/day), sometimes in association to additional drugs. One patient died before any therapy and one patient was treated with steroid alone. If the patients were included in therapeutic LCH II and LCH III trials, VP16 (N = 2) or methotrexate (N = 4) was administered according to the randomization of the trial. The three patients with MI at relapse were each treated at their initial LCH diagnosis with the same doses of prednisone and vinblastine. At relapse, one patient was treated with vinblastine and prednisone, one with 2-chlorodeoxyadenosine (2-CdA) alone, and one received VP16, cytarabine, and cyclosporine. After 6 weeks of treatment, according to the evaluation criteria of the Histiocyte Society, the disease status was considered as non-active in four patients (11%), active disease better in 29 (78%), including one who had received only steroid treatment, active disease—stable in three (8%) and lastly active disease—worse in one patient (2.7%) who died from the disease.

The disease activity score decreased for all patients, except those who died from the disease, however it remained above five in six patients, which can be considered a poor response. All treated patients presented with decreased volume of MI; 15 patients had a residual mass after 6 weeks. Even in cases with poor response to the initial therapy, MI was not considered to be life threatening, or even as a therapeutic target in the latter course of therapy. Sixteen patients experienced at least one disease relapse and the 5-year relapse rate was only 45% (95% CI, 26–62%; Fig. 3B). Three of these relapses involved the thymus in patients who did not have MI at initial diagnosis, at 1 or 3 years after the initial diagnosis. Treatment of refractory disease or relapse was managed according to national guidelines, when available. Four patients received 2-CdA and cytarabine as a second-line therapy, and four patients received monotherapy with 2-CdA.

The overall survival (Fig. 3A) was 87% (95% CI, 69–95%). Five patients died. One of them was the youngest child of the cohort, a 15-day-old newborn; a few days after diagnosis and before receiving any therapy, this patient experienced multi-organ failure and sudden death, possibly due to tracheal compression. Another patient died during the course of the disease due to a parenteral nutrition overinfusion. One patient, whose disease was initially controlled, died during a relapse of the disease involving risk organs that was being treated with vinblastine, steroid, and procarbazine; the cause of death was respiratory distress, related to the disease itself. Two patients with multivisceral refractory disease were treated with 2-CdA and cytarabine, and died from sepsis. Among the 35 patients treated with systemic therapy, severe infection was observed in seven patients during the first course of systemic therapy. One patient presented both cytomegalovirus and *Pneumocystis jiroveci* infections, and six patients presented septicemia (*Staphylococcus aureus* in three cases, and one case each of group B...
Langerhans histiocytosis with thymic and/or mediastinal localization is rarely reported and probably under-diagnosed. Review of the literature from 1963 to 2010 identified 50 described cases, almost always reported as single case reports [5,6,8,9,11–16,19–21,23–36] and infrequently as small patient surveys (including four, four, four, five, and three cases, respectively) [7,10,17,18,22]. In the present study, we investigated a large cohort of pediatric patients with LCH and estimated that mediastinal and/or thymic involvement occurs in up to 2.6%. This estimation is based on all cases included in the national French registry since 1983. The proportion was found to be largely dependent on age, ranging from about 7% in infants less than 1 year of age, and decreasing with age to less than 1% in older children. It is noteworthy the total median age of previously reported cases (Table I) was 1.55 years; the literature included six adults older than 18 years [31–36].

The radiological findings in our cohort confirmed the previously reported morphological description and provide greater insight into the natural history of thymic involvement. A majority of patients had an anterior mediastinal or thymic enlargement [18]. CT scan revealed calcification in about half of our patients as previously described [13,16,21], which was not seen on standard chest X-rays. Of note, we found these calcifications exclusively in the thymus as has also been previously reported [9] but not in the mediastinal lymph nodes. Another sign of disease involvement was the presence aeric cysts in the thymus, described in children [10] and in adults [35,36]. We also found a notable discrepancy between the radiological description and the clinical symptoms; only a third of cases presented symptoms related to MI, while two-thirds had no local symptoms despite a huge volume of thymus involvement.

In addition to providing a description of MI, our study found that such involvement was always associated with multi-systemic diseases, with half of the patients having affected risk organs. This is consistent with the majority of cases reported in the literature (Table I), although some cases have been reported as exclusively localized to the thymus [21,23]. The distribution of the different organ involvement is different in patients with MI, compare to the common presentation of LCH in children [4]. Patients with MI had less frequently bone lesions and more frequently skin involvement contrary to patients without MI. This difference is probably associated to the younger age of the majority of our patients; the median age of our patients was 0.7 years versus 3.5 years for all children with LCH [4]. Consequently to a more aggressive and extended disease, systemic therapy was prescribed in almost all of the patients with MI. The proportion of refractory patients seems in agreement with what has been commonly observed in patients with risk organ involvement [39].

Although thymic involvement may result in significant adverse symptoms, it is not considered as a major organ determining the prognosis. Four out of the five deaths observed in this survey were not related to MI, but rather to the already known risk organs, the toxicity of second-line therapy approaches (like 2-CdA with cytarabine), or supportive care (parenteral nutrition). However, although the overall prognosis was not related to MI, we were surprised by the high rate of severe infections; 7 out of 37 patients is far higher than the rate commonly observed with the standard vinblastine and steroid courses [40]. This rate of infections is closer to the rate observed during induction of acute lymphoblastic leukemia [41]. This infection rate may be partially explained by the young age of the patients, as well as by the alteration of immunocompetence by the thymus involvement, as transiently observed in six cases. Because such patients had several infection risk factors at the same time such as young age, central line, skin effraction, thymus disease, and chemotherapy and they must probably have to be considered as being at a high risk of infection.

DISCUSSION

Langerhans histiocytosis with thymic and/or mediastinal localization is rarely reported and probably under-diagnosed. Review of the literature from 1963 to 2010 identified 50 described cases, almost always reported as single case reports [5,6,8,9,11–16,19–21,23–36] and infrequently as small patient surveys (including four, four, four, five, and three cases, respectively) [7,10,17,18,22]. In the present study, we investigated a large cohort of pediatric patients with LCH and estimated that mediastinal and/or thymic involvement occurs in up to 2.6%. This estimation is based on all cases included in the national French registry since 1983. The proportion was found to be largely dependent on age, ranging from about 7% in infants less than 1 year of age, and decreasing with age to less than 1% in older children. It is noteworthy the total median age of previously reported cases (Table I) was 1.55 years; the literature included six adults older than 18 years [31–36].
organ involvement. Diagnosis of MI could be difficult with plain X-rays, and CT is very useful in this cases. Thymic calcification on CT is the most typical lesion found. The possible association with immunodeficiency and the more frequent occurrence of severe infection must be noted, and such patients should be considered to be at a high risk of infections during their initial therapy.

ACKNOWLEDGMENTS

The French Histiocytosis registry is supported by grants from the Institut de Veille Sante, and Inserm. This project received constant and unlimited support from the Association Histiocytose France, a grant from the association “La Petite Maison dans la prairie” and a grant from the RMHE. The authors thank the patients and their families for their participation in this study. This study is based on research from the Centre de Reference des Histiocytoses and was supported by the Societe d’Hemat Immunologie Pediatrique and the Societe Francaise des Cancers de l’Enfant.

REFERENCES

1. Badalian-Very G, Vergiolo JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919–1923.
2. The French Langerhans’ Cell Histiocytosis Study Group. A multicentre retrospective survey of Langerhans’ cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child 1996;75:17–24.
3. Haapt R, Minkov M, Astigarraga I, et al. Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer 2013;60:175–184.
4. Guyot-Goubin A, Donadieu J, Barkawi M, et al. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000–2004. Pediatr Blood Cancer 2008;51:71–75.
5. Beatty EC. Eosinophilic granuloma of parotid gland and thymus. Am J Dis Child 1963;105:119–122.
6. Nakata H, Suzuki H, Sato Y, et al. Histiocytosis X with anterior mediastinal mass as its initial manifestation. Pediatr Radial 1982;12:84–85.
7. Siegal GP, Detterer LP, Rosai J. Histiocytosis X (Langerhans’ cell granulomatosis) of the thymus. A clinicopathologic study of four childhood cases. Am J Surg Pathol 1985;9:117–124.
8. Eilkhani F, Shirkhoda A, Cangir A. Cavitation of a mediastinal mass following chemotherapy for histiocytosis-X. CT demonstration. J Comput Assist Tomogr 1986;10:130–132.
9. Bove KE, Hutmacher P, Wong KY. Thymus in untreated systemic histiocytosis X. Pediatr Pathol 1985;4:99–115.
10. Abrahamson SJ, Berdon WE, Reilly RL, et al. Cavitition of anterior mediastinal masses in children with histiocytosis-X. Report of four cases with radiographic, pathologic findings and clinical follow up. Pediatr Radial 1987;17:10–14.
11. Fasani S, Barbati D, Graziani M, et al. Thymic involvement in acute disseminated histiocytosis X. Rays 1987;12:39–45.
12. Shuangshoti S, Srisuphan P. Histiocytosis X Overlapping form between Letterer–Siwe disease and Hand–Schuller–Christian disease with advanced thymus involvement and obstructive jaundice. J Med Assoc Thai 1987;70:344–350.
13. Odagiri K, Niishira K, Hatakeyama S, et al. Anterior mediastinal masses with calcifications on CT in children with histiocytosis-X (Langerhans cell histiocytosis). Report of two cases. Pediatr Radial 1991;21:550–551.
14. Mogal M, Hartman G, Donaldson S, et al. Langerhans’ cell histiocytosis presenting with the superior vena cava syndrome: A case report. Med Pediatr Oncol 1993;21:456–459.
15. Samnes TE, Auringer ST, Preston AA. Thymic calcifications in histiocytosis X. Pediatr Radial 1993;23:204–205.
16. Eftekhari F, Shirkhoda A, Cangir A. Cavitation of a mediastinal mass following chemotherapy for histiocytosis-X. Report of four cases with radiographic, pathologic findings and clinical follow up. Pediatr Radial 1993;17:10–14.
17. Fasani S, Barbati D, Graziani M, et al. Pulmonary and mediastinal lesions in children with Langerhans cell histiocytosis. Pediatr Radial 1997;27:873–876.
18. Heller GD, Haller JO, Berdon WE, et al. Punctate thymic calcification in infants with untreated Langerhans’ cell histiocytosis: Report of four new cases. Pediatr Radial 1999;29:813–815.
19. Junewick JJ, Fritzgerald NE. The thymus in Langerhans’ cell histiocytosis. Pediatr Radial 1999;29:904–906.
20. Tas RK, Melotti M, Comerci SC. Two-year-old girl with thymic calcifications and liver function abnormalities: A case from the AICR2 film panel. Acad Radial 1999;6:599–601.
21. Donnelly LF, Fresh DP. Langerhans’ cell histiocytosis showing low-attenuation mediastinal mass and cystic lung disease. J Pediatr 2001;138:728–734.
22. Elliott M, Koki G, Abernethy LJ, et al. Spontaneous resolution of isolated thymic Langerhans cell histiocytosis. Med Pediatr Oncol 2002;38:274–276.
23. Liu L, Krauthak T, Ties MM, et al. Cutaneous-Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer 2006;46:66–71.
24. Hernandez Perez JM, Francoque CT, Rodriguez S, et al. The Langerhans cell histiocytosis with thymic localization as initial and exclusive place. An Med Interna 2007;24:487–499.
25. Khudilkar UN, Rao ATK, Kurahao S, et al. Langerhans cell histiocytosis of mediastinal node. Indian J Pediatr 2007;74:294–296.
26. Stalnacke H, Laerencac B, Kato J, et al. Incidence of Langerhans cell histiocytosis in children: A population-based study. Pediatr Blood Cancer 2008;51:76–81.
27. Yagi T, Yama A, Uesu A, et al. Thymic Langerhans cell histiocytosis mimicking lymphoma. Pediatr Blood Cancer 2008;51:833–835.
28. Hatakeyama N, Hori T, Yamamoto M, et al. An infant with self-healing cutaneous Langerhans cell histiocytosis. A case report. Pediatr Blood Cancer 2009;53:229–231.
29. Trote M, Webster MA, Jacobs TS, et al. Disseminated langerhans cell histiocytosis-related sudden unexpected death in infancy. Fetal Pediatr Pathol 2009;28:39–44.
30. Crawley AJ, Guilarman RF. Langerhans cell histiocytosis with intrathymic calcifications and cavitation. Pediatr Radial 2010;40:582.
31. Novak L, Castro CY, Listinsky CM. Multiple Langerhans cell nodules in the neck. Arch Pathol Lab Med 2005;129:472–475.
32. Gilcrease MZ, Rajan B, Otosro MW, et al. Localized thymic Langerhans’ cell histiocytosis and its relationship with myasthenia gravis. J Pediatr 1997;121:134–138.
33. Pescarmona E, Rendina EA, Racc C, et al. Histiocytosis X and lymphoid follicular hyperplasia of the thymus. Histopathology 1989;14:645–470.
34. Lee BH, George S, Katak JG. Langerhans cell histiocytosis involving the thymus. A case report and review of the literature. Arch Pathol Lab Med 2003;127:294–297.
35. Wulke P, Jr., Suster S. Langerhans’ cell histiocytosis of the thymus associated with multisystemic thymic cyst. Hum Pathol 2000;31:1532–1535.
36. Kawano R, Hata E, Ikeda S, et al. Langerhans cell histiocytosis: Persistence of bronchogenic and thymic cysts in the thymus. Gen Thorac Cardiovasc Surg 2008;56:74–76.
37. Merten DF. Diagnostic imaging of mediastinal masses in children. J Pediatr 1999;135:825–832.
38. Donadieu J, Pique T, Bertrand F, et al. A new clinical score for disease activity in Langerhans cell histiocytosis. Pediatr Blood Cancer 2007;47:322–326.
39. Minkov M, Gross N, Hejger A, et al. Response to initial treatment of multisystem Langerhans cell histiocytosis: An important prognostic indicator. Med Pediatr Oncol 2002;39:581–585.
40. Gudler H, Gross N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr 2003;138:728–734.